International Journal of Clinical Case Reports 2024, Vol.14, No.5, 253-261 http://medscipublisher.com/index.php/ijccr 260 Raijada D.K., Wac K., Greisen E., Rantanen J., and Genina N., 2021, Integration of personalized drug delivery systems into digital health, Advanced Drug Delivery Reviews, 176: 113857. https://doi.org/10.1016/j.addr.2021.113857 PMID: 34389172 Roddick A., and Zheng S., 2018, Comparative cardiovascular efficacy of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 agonists-a network meta-analysis, Diabetes, 67(Supplement_1):427-P https://doi.org/10.2337/DB18-427-P Rothenberger S.D., Gellad W.F., Luo J., Feldman R., and Mahtta D., 2021, Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: acost-effectiveness and price target analysis, The Lancet Diabetes and Endocrinology, 9(12): 825-836. https://doi.org/10.1016/S2213-8587(21)00240-0 PMID: 34656210 Sabouret P., Bocchino P., Angelini F., D'Ascenzo F., Galati G., Fysekidis M., de Ferrari G.M., Fischman D.L., Bhatt D.L., and Biondi-Zoccai G., 2022, Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis, Minerva Cardiology and Angiology, 71(2): 199-207. https://doi.org/10.23736/S2724-5683.22.05900-2 PMID: 35195376 Salmen T., Rizvi A., Rizzo M., Pietrosel V., Bica I., Diaconu C.T., Potcovaru C.G., Salmen B.M., Coman O., Bobircă A., Stoica R., and Stoian A.M.P., 2023a, Antidiabetic molecule efficacy in patients with type 2 diabetes mellitus-a real-life clinical practice study, Biomedicines, 11(9): 2455. https://doi.org/10.3390/biomedicines11092455. PMID: 37760896 PMCID: PMC10525559 Salmen T., Serbanoiu L.I., Bica I.C., Serafinceanu C., Muzurović E.M., Janež A., Busnatu Ș., Banach M., Rizvi A., and Stoian A.M.P., 2023b, A critical view over the newest antidiabetic molecules in light of efficacy-a systematic review and meta-analysis, International Journal of Molecular Sciences, 24(11): 9760. https://doi.org/10.3390/ijms24119760. PMID: 37298707 PMCID: PMC10253587 Scheen A., 2016, Precision medicine: the future in diabetes care?, Diabetes Research and Clinical Practice, 117: 12-21. https://doi.org/10.1016/j.diabres.2016.04.033 PMID: 27329017 Scheen A., 2018, Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists, Diabetes Research and Clinical Practice, 143: 88-100. https://doi.org/10.1016/j.diabres.2018.06.008 PMID: 29944969 Song R.S., Sun K., Wang Y.X., Liu S.K., and Bu Y.Y., 2024, Synthetic microbial communities: redesigning genetic pathways for enhanced functional synergy, Molecular Microbiology Research, 14(1): 39-48. https://doi.org/10.5376/mmr.2024.14.0005. Tomlinson B., Hu M., Zhang Y., Chan P., and Liu Z., 2016, An overview of new GLP-1 receptor agonists for type 2 diabetes, Expert Opinion on Investigational Drugs, 25: 145-158. https://doi.org/10.1517/13543784.2016.1123249 PMID: 26587691 Tonelli M., and Straus S.E., 2022, Increasing societal benefit from cardiovascular drugs, Circulation, 146(21): 1627-1635. https://doi.org/10.1161/CIRCULATIONAHA.122.059032 PMID: 36409780 Wright A., Carr M., Kontopantelis E., Leelarathna L., Thabit H., Emsley R., Buchan I., Mamas M.A., van Staa T.P., Sattar N., Ashcroft D.M., and Rutter M.K., 2022, Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes, Diabetes Care, 45(4): 909-918. https://doi.org/10.2337/dc21-1113 PMID: 35100355 Xie Y., Bowe B., Gibson A.K., McGill J.B., Maddukuri G., Yan Y., and Al‐Aly Z., 2020, Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases, Diabetes Care, 43: 2859-2869. https://doi.org/10.2337/dc20-1890 Yang S., He W., Zhao L., and Mi Y., 2022, Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis, PLoS ONE, 17: 0267025. https://doi.org/10.1371/journal.pone.0267025 PMID: 35421174 PMCID: PMC9009659
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==